Retrospective Comparison of Standard Clotting Tests and Novel Clot Waveform Parameters in Dogs Using the Turbidimetric ACL-TOP CTS 300 Coagulation Analyzer

Overview

Journal J Vet Diagn Invest

Specialty Veterinary Medicine

Date 2018 Sep 12

PMID 30204058

Citations 1

Authors

Hamsini Yagneswar

Jeffrey M Todd

Leslie C Sharkey

Aaron Rendahl

Kelly Tart

Affiliations

Soon will be listed here.

Abstract

Clot waveforms are generated by coagulation analyzers, such as the ACL-TOP, that utilize photo-optical turbidimetric methods to measure prothrombin time (PT) and activated partial thromboplastin time (aPTT), which are standard clotting tests (SCTs). Additional quantitative clot waveform analysis (CWA) parameters include maximum velocity of the PT curve (PT1d), maximum acceleration of the aPTT curve (aPTT2d), and their change in optical density (ODdelta). We explored the potential for CWA to contribute unique information compared to SCTs and quantitative fibrinogen assay (QFA) in dogs with clinical indications for laboratory evaluation of coagulation. We retrospectively evaluated the frequency and agreement between normal, high, and low values of CWA and SCTs for 203 dogs relative to reference intervals (RIs). Most dogs had SCTs within RIs, but most CWA values were high regardless of whether SCT values were within, below, or above the RI. Agreement between SCTs and CWA was slight (kappa <30%). Clinically significant bleeding was noted in 28 of 203 (14%) dogs. SCTs were not different between bleeders and non-bleeders. Median QFA, PT1d, aPTTdelta, and aPTT2d values were statistically significantly higher than RIs in non-bleeders compared to bleeders, whose median values were not below RI. Compared with SCTs, CWA identified differences between the 2 groups. However, wide overlap between the 2 groups limits the use of CWA to clinically discriminate between bleeders and non-bleeders in a heterogeneous population of dogs. Further studies on the diagnostic utility of CWA in coagulopathic dogs are needed.

Citing Articles

Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.

Kanouchi K, Narimatsu H, Shirata T, Morikane K Health Sci Rep. 2021; 4(2):e258.

PMID: 33738342 PMC: 7953360. DOI: 10.1002/hsr2.258.

References

Toh C, Giles A . Waveform analysis of clotting test optical profiles in the diagnosis and management of disseminated intravascular coagulation (DIC). Clin Lab Haematol. 2002; 24(6):321-7. DOI: 10.1046/j.1365-2257.2002.00457.x. View

Mann K, Butenas S, Brummel K . The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003; 23(1):17-25. DOI: 10.1161/01.atv.0000046238.23903.fc. View

Toh C, Ticknor L, Downey C, Giles A, Paton R, Wenstone R . Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation. Intensive Care Med. 2003; 29(1):55-61. DOI: 10.1007/s00134-002-1557-2. View

Eckman M, Erban J, Singh S, Kao G . Screening for the risk for bleeding or thrombosis. Ann Intern Med. 2003; 138(3):W15-24. DOI: 10.7326/0003-4819-138-3-200302040-00011-w1. View

Shima M . Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol. 2004; 41(1 Suppl 1):125-31. DOI: 10.1053/j.seminhematol.2003.11.021. View

Kitchens C . To bleed or not to bleed? Is that the question for the PTT?. J Thromb Haemost. 2005; 3(12):2607-11. DOI: 10.1111/j.1538-7836.2005.01552.x. View

Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y . The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost. 2006; 4(2):377-84. DOI: 10.1111/j.1538-7836.2006.01730.x. View

Matsumoto T, Wada H, Nishioka Y, Nishio M, Abe Y, Nishioka J . Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2006; 12(2):185-92. DOI: 10.1177/107602960601200206. View

Wiinberg B, Jensen A, Rozanski E, Johansson P, Kjelgaard-Hansen M, Tranholm M . Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. Vet J. 2007; 179(1):121-9. DOI: 10.1016/j.tvjl.2007.08.022. View

10.

White H, Gallo R, Cohen M, Steg P, Aylward P, Bode C . The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. Am Heart J. 2008; 157(1):125-31. DOI: 10.1016/j.ahj.2008.08.019. View

11.

Walsh T, Stanworth S, Prescott R, Lee R, Watson D, Wyncoll D . Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. Crit Care Med. 2010; 38(10):1939-46. DOI: 10.1097/CCM.0b013e3181eb9d2b. View

12.

Solano C, Zerafa P, Bird R . A study of atypical APTT derivative curves on the ACL TOP coagulation analyser. Int J Lab Hematol. 2010; 33(1):67-78. DOI: 10.1111/j.1751-553X.2010.01248.x. View

13.

Lier H, Bottiger B, Hinkelbein J, Krep H, Bernhard M . Coagulation management in multiple trauma: a systematic review. Intensive Care Med. 2011; 37(4):572-82. DOI: 10.1007/s00134-011-2139-y. View

14.

Saavedra P, Lara Garcia A, Zaldivar Lopez S, Couto G . Hemostatic abnormalities in dogs with carcinoma: a thromboelastographic characterization of hypercoagulability. Vet J. 2011; 190(2):e78-e83. DOI: 10.1016/j.tvjl.2011.02.025. View

15.

Mehran R, Rao S, Bhatt D, Gibson C, Caixeta A, Eikelboom J . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23):2736-47. DOI: 10.1161/CIRCULATIONAHA.110.009449. View

16.

Ndrepepa G, Schuster T, Hadamitzky M, Byrne R, Mehilli J, Neumann F . Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012; 125(11):1424-31. DOI: 10.1161/CIRCULATIONAHA.111.060871. View

17.

Maunder C, Costa M, Cue S, Crawford E, Papasouliotis K, Murphy K . Measurement of prothrombin time and activated partial thromboplastin time in citrated whole blood samples from clinically ill dogs following storage. J Small Anim Pract. 2012; 53(9):531-5. DOI: 10.1111/j.1748-5827.2012.01255.x. View

18.

Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H . Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report. Haemophilia. 2012; 19(2):330-7. DOI: 10.1111/hae.12024. View

19.

McHugh M . Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22(3):276-82. PMC: 3900052. View

20.

Friedrichs K, Harr K, Freeman K, Szladovits B, Walton R, Barnhart K . ASVCP reference interval guidelines: determination of de novo reference intervals in veterinary species and other related topics. Vet Clin Pathol. 2012; 41(4):441-53. DOI: 10.1111/vcp.12006. View